NCT05298592
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated CNS metastases; Patients with central nervous system (CNS) metastases as the only site of active disease; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05298592